Tacrolimus dose requirement in relation to donor and recipientABCB1 andCYP3A5 gene polymorphisms in Chinese liver transplant patients
- 20 April 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 12 (5), 775-780
- https://doi.org/10.1002/lt.20709
Abstract
The aim of this study was to investigate whether the heterogeneity in tacrolimus dose requirement is associated with ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients during the first month after transplantation. ABCB1 and CYP3A5 genotyping was performed using the polymerase chain reaction restriction sites polymorphism–based procedure in Chinese liver transplant recipients (n = 50) and their corresponding donors (n = 50). Tacrolimus whole‐blood trough concentrations were measured by immunoassays on the IMx analyzers (Abbott Diagnostics Laboratories, Abbott‐Park, IL). Doses required to achieve target blood concentrations and dose‐adjusted trough concentrations (concentration/dose [C/D] ratios) were compared among patients according to allelic status of ABCB1 and CYP3A5. The ABCB1 3435CC was observed in 23 subjects (23%), whereas 64 (64%) carried 3435CT and 13 (13%) carried 3435TT. The CYP3A5*1/*1 was observed in 13 subjects (13%), 50 (50%) carried *1/*3, and 37 (37%) carried*3/*3. The tacrolimus C/D ratios were obviously lower in recipients carrying ABCB1 3435CC genotype. For CYP3A5, recipients who received organs from CYP3A5*3/*3 donors had higher C/D ratios. But the donors' ABCB1 and recipients' CYP3A5 genotype did not affect the recipients' pharmacokinetics. Analysis of the combination of recipients' ABCB1 and donors' CYP3A5 genotypes revealed that the tacrolimus C/D ratios were significantly lower in the ABCB1 3435CC–carrying recipients, regardless of donors' CYP3A5 genotype. In conclusion, our finding suggests that the recipients' ABCB1 and donors' CYP3A5 genotype affect the tacrolimus dose requirements. ABCB1 C3435T polymorphism is a major determinant of tacrolimus trough concentration in Chinese liver transplant recipients, and recipients with 3435CC genotype will require higher dose of tacrolimus. Liver Transpl 12:775–780, 2006. © 2006 AASLD.Keywords
This publication has 17 references indexed in Scilit:
- The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patientsPharmacogenetics, 2004
- Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene PolymorphismThe Journal of Clinical Pharmacology, 2004
- Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimusCancer Cell, 2003
- Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugsPharmacogenomics, 2003
- Genetic Polymorphisms of the HumanMDR1Drug TransporterAnnual Review of Pharmacology and Toxicology, 2003
- Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirementTransplantation, 2002
- Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 geneClinical Pharmacology & Therapeutics, 2002
- Identification of functionally variant MDR1 alleles among European Americans and African AmericansClinical Pharmacology & Therapeutics, 2001
- Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expressionNature Genetics, 2001
- Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProceedings of the National Academy of Sciences, 2000